(MedPage Today) -- A majority of patients with chronic myelogenous leukemia achieved a deep molecular response with imatinib-based therapy, which correlated with improved long-term and progression-free survival, a randomized trial showed. via MedPageToday.com - medical news plus CME for physicians Read More Here..
No comments:
Post a Comment